In-vivo CRISPR editing gene therapy (Orna)

N/A

Report date: 2024/10/28 10:40:10

Base Information

Drug NameIn-vivo CRISPR editing gene therapy (Orna)
Drug Alias NameN/A
ClassificationCell and gene therapy > Gene therapy > Gene editing
Mechanisms of ActionGene transference
TargetsUpdating
Therapy Area/IndicationsSickle Cell Crisisbeta-Thalassemia
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesOrna Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesOrna Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsSickle Cell Crisisbeta-Thalassemia
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A